Published in Genomics and Genetics Weekly, December 10th, 2004
One of the 3 studies, presented at the 25th Annual Meeting of the American College of Toxicology (ACT) is a double-blind, placebo controlled trial of 110 patients. No significant adverse effects where found in the 70 clinically depressed patients receiving 400-600 mcg of chromium as chromium picolinate orally for up to 8 weeks.
Separately, new research from Purdue University, published in the International Journal of Sports Nutrition and Exercise Metabolism,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.